

# WORLD VACCINE

CONGRESS  
EUROPE

22<sup>ND</sup> ANNUAL

19-21 October, 2021

Palau de Congressos de Catalunya  
Barcelona, Spain

Research,  
Development and  
Strategic Partnering  
for the Global Vaccine  
Industry.

CO-LOCATED WITH

CREATED BY

WORLD VETERINARY  
VACCINE CONGRESS

IMMUNO ONCOLOGY  
PROFILING CONGRESS

SPARK SOMETHING  
TERRAPINN

CONFERENCE TRACKS INCLUDE

WORLD VACCINE  
INFLUENZA &  
RESPIRATORY

WORLD VACCINE  
EMERGING &  
RE-EMERGING

WORLD VACCINE  
CLINICAL  
TRIALS

WORLD VACCINE  
BIOPROCESSING &  
MANUFACTURING

WORLD VACCINE  
TECHNOLOGY

WORLD VACCINE  
ANTIMICROBIAL  
RESISTANCE

WORLD VACCINE  
PARTNERSHIPS

[terrappinn.com/wvceu-2021prospectus](http://terrappinn.com/wvceu-2021prospectus)

[terrappinn.com/vetvax-prospectus2021](http://terrappinn.com/vetvax-prospectus2021)

[terrappinn.com/immuno-prospectus2021/](http://terrappinn.com/immuno-prospectus2021/)

# THE VACCINE INDUSTRY MEETING PLACE

The World Vaccine Congress is an award-winning series of conferences and an exhibition that has grown to become the largest and most established vaccine meeting of its kind across the globe. Our credibility is shown through the prestigious scientific advisory board that spend months of hard work creating a new and topical agenda, year on year.


Now in its 22nd annual, the World Vaccine Congress Europe, together with the co-located Veterinary Vaccine and Immuno-Oncology congresses, will continue to bring experts from the whole value chain under one roof, where you get to meet decision makers in the areas that are most applicable for your business offering. It will offer the chance to come together at a time where the disruption of COVID-19 has meant being able to network, learn and collaborate is as important as ever.

With 800+ potential customers in attendance there will be opportunities to find contacts who need to find solutions to challenges around the political, commercial and scientific issues in manufacturing, clinical trials, strategy, regulation, veterinary vaccines, immune profiling, AMR, respiratory, influenza, therapeutic and emerging diseases.



150 Speakers	12 Conference Themes	50+ Exhibitors
Workshops	800+ Attendees	Partnering System

## CONFERENCE THEMES



## EVENT FEATURES:

### COVID-19 HUB

A dedicated area for the latest updates and presentations from those leading the race and delivery of a vaccine.

### WORLD LEADING PRESENTATIONS

Original presentations from the most informed Industry experts on COVID-19 and all vaccine related topics. Genuine leaders that you can learn from and take away tangible insights for your business.

### THE STRONGEST AGENDA YET

Governed by our Scientific Advisory Board, which includes: 23 leading pioneers of the vaccine industry that have ensured the agenda, topics and speakers are relevant and cutting edge, so that your 3 days with us will be the most memorable yet.

### INTERNATIONAL DECISION MAKERS

Hear from over 150+ senior speakers across the from the WHO, CEPI, European Commission, EMA, FDA in government to C-level executives from GSK, Merck, Pfizer, Janssen, Sanofi and innovative biotechs. This is your best chance of the year to meet and network with hundreds of like-minded peers at Europe's biggest vaccine meeting.

### NEW WORKSHOPS, TRACKS AND TWO CO-LOCATED CONFERENCES

Attend focused sessions across multiple tracks AND two co-located congresses. Take this unique opportunity to gain not only the sessions at the World Vaccine congress, but also the 7th World Veterinary Vaccines Congress and 6th Immuno-Oncology Profiling World Congress.

### PANEL DEBATES

We have curated panels of 4-5 industry experts to debate some of your burning questions. You'll be able to watch them live and pose questions directly the panelists.

### NETWORKING

There are more networking opportunities, with three days' worth of content, extended breaks, multiple drinks receptions and two co-located events, you will have even more time to meet cross sector contacts with over 800 attendees.

# OUR SCIENTIFIC ADVISORY BOARD



**Dr Ofer Levy**  
Harvard Medical School



**Dr Miles Carroll**  
Public Health England



**Dr Gregory Poland**  
Mayo Clinic



**Dr Annaliesa Anderson**  
Pfizer



**Prof Hanneke Schuitemaker**  
Janssen



**Prof Albert Osterhaus**  
RIZ, Hannover University



**Prof Jeffrey Almond**  
University of Oxford



**Dr Jan Poolman**  
Janssen



**Dr Jerald Sadoff**  
Janssen



**Dr Antu Dey**  
IAVI



**Dr Konrad Stradler**  
CEVA



**Dr Roy Baynes**  
MSD



**Dr Nathalie Garcon**  
Bioaster



**Dr Cyril Gay**  
USDA



**Dr Gregory Glenn**  
Novavax



**Prof Stanley Plotkin**  
Vaxconsult & University of Pennsylvania School of Medicine



**Dr Bruce Gellin**  
Sabin Vaccine Institute



**Dr George Siber**  
ClearPath



**Dr Walter Straus**  
MSD



**Dr Rino Rappuoli**  
GSK



**Dr Mahesh Kuman**  
Zoetis



**Dr Bernard Vallat**  
Former OIE



**Dr Ralf Clemens**  
GRID Rio



**Prof Fred Zepp**  
University of Mainz



**Dr Joris Vandeputte**  
IABS



**Dr Lorne Babiuk**  
University of Alberta



**Dr Maria Elena Bottazzi**  
Baylor College of Medicine & Texas Children's Hospital



**Dr Jerome Kim**  
IVI



**Prof Helen McShane**  
University of Oxford



**Dr Lazlo Radvanyi**  
OICR



**Dr Peter Hotez**  
Baylor College of Medicine & Texas Children's Hospital



**Dr Christiane Gerke**  
Institute Pasteur



**Dr Leonard Friedland**  
GSK



**Dr Roman Chicz**  
Sanofi



**Prof Mark Davis**  
Stanford University



**Dr Paul Offit**  
The Children's Hospital of Philadelphia




**Prof Bali Pulendran**  
Stanford University



**Prof Heidi Larson**  
LSHTM

# TOPICS



# BARCELONA AGENDA OVERVIEW

## Oct 19, 2021

Oct 19 Day 1 CET	KEYNOTES			
9:00 – 9:30	<b>Keynote address: An overview of the UK Covid-19 vaccination programme – from strategy to delivery</b> <b>Dr Jonathan Van Tam, Deputy Chief Medical Officer, England</b>			
9:30 – 10:30	<b>Keynote panel: Efficacy data from COVID vaccines and preparedness for variants</b> <ul style="list-style-type: none"> <li>- Global vaccine effectiveness rates: Are effectiveness data supporting the efficacy from clinical trials?</li> <li>- What is being seen in vaccine effectiveness data and impact across products and across populations?</li> <li>- How will the different vaccines interact in the immune system? Can we mix &amp; match and is that safe?</li> <li>- Does prevention of transmission and protection against mild disease really matter?</li> <li>- Are we prepared for variants?</li> </ul> <b>Dr Kate O'Brien, Director of Vaccines, WHO</b> <b>Dr Matthew Snape, Professor in Paediatrics &amp; Vaccinology, University of Oxford</b> <b>Dr Randall Hyer, Head of Medical Affairs, Moderna</b> <b>Dr Hanneke Schuitemaker, VP, Viral Vaccine Discovery and Translational Medicine, Janssen Vaccines</b> <b>Dr Rino Rappuoli, Chief Scientist, GSK Vaccines</b> <b>Dr Prakash Bhuyan, MD, Vice President, Head of Infectious Diseases, Clinical Development, AstraZeneca</b>			
10:30 – 11:00	Expo & Partnering Morning Break			
11:00 – 12:00	<b>Interactive roundtables</b>			
11:00 – 12:00	<b>Regulatory safety in vaccines - Title TBC</b> <b>Senior representative, SGS</b>	<b>Are we ready and prepared for the upcoming flu season?</b>	<b>Deployment &amp; procurement of COVID vaccines</b>	<b>Next generation vaccines – what will these look like and with what technology?</b>
11:00 – 12:00	<b>Patents and the role of big pharma in and manufacturers during a pandemic – has a new model been built from this experience?</b>	<b>Roundtable title TBC</b> <b>Senior representative, PRA Health Sciences</b>		<b>Currently accepting roundtables</b> <b>Contact <a href="mailto:Wing-yun.Cheung@Terrapinn.com">Wing-yun.Cheung@Terrapinn.com</a></b> <b>or</b> <b><a href="mailto:Nadia.Konneh@Terrapinn.com">Nadia.Konneh@Terrapinn.com</a></b>
12:00 – 13:30	Expo & Partnering Lunch Break			
Tracks	COVID-19	Clinical Development	Immune Profiling	
Afternoon Sessions	<b>13:30 – 14:30 Panel: How will coronavirus evolve as it establishes itself in the human population? Flu-like, Rhino-like or measles-like?</b> <b>Professor Jeffrey W. Almond PhD. FMedSci. Visiting Professor of Microbiology, University of Oxford</b>	<b>13:30 Use of neutralisation studies to monitor and inform immunisation strategies</b> <b>Dr Nick Gent, Senior Medical Adviser (Emergency Response Department), PHE</b> <b>13:45 Animal Study</b> <b>Reproducibility: Problems and Solutions</b>	<b>13:30 Signatures for distinct disease endotypes and progression to active disease in tuberculosis</b> <ul style="list-style-type: none"> <li>- Transcriptomic and metabolomic signatures that allow diagnosis and prognosis of tuberculosis</li> <li>- Prognostic markers of progression to active disease will pave the way to</li> </ul>	

	<p><b>Dr Sharon Peacock</b>, Executive Director, <b>COVID-19 Genomics UK (COG-UK) consortium</b></p> <p><b>Dr Helena Maier</b>, Group Leader, Coronaviruses, <b>Pirbright</b></p>	<p><b>Eric Ibsen</b>, CEO, <b>Studylog Systems, Inc.</b></p>	<p>biomarkers which can predict vaccine efficacy</p> <p><b>Professor Stefan Kaufmann</b>, Director Emeritus, Immunology, <b>Max Planck Institute for Infection Biology</b></p>
		<p>14:00 <b>Insights from the world's first COVID-19 human challenge study on young adults – final title TBC</b></p> <p><b>Senior representative, hVivo</b></p>	<p>14:00 <b>Using systems vaccinology/ biology to understand host responses to childhood vaccinations</b></p> <p><b>Daniel O'Connor</b>, University Research Lecturer, Senior Bioinformatician, <b>Oxford Vaccine Group</b></p>
	<p>14:30 <b>UK's data and interpretation from COVID-19 variants</b></p> <p><b>Dr Alessandro Carabelli</b>, <b>COVID-19 Genomics UK (COG-UK) consortium</b></p>	<p>14:30 <b>Developing a Global Informatics Framework In Preparation for Disease X – final title TBC</b></p> <p><b>Senior representative, PRA Health Sciences</b></p>	<p>14:30 <b>A modern approach to traditional virology research</b></p> <p><b>Reserved for Nexcelom</b></p>
			<p>14:45 <b>Accelerating the next generation of immune medicine with functional phenotyping - title tbc</b></p> <p><b>Reserved for IsoPlexis</b></p>
	<p>15:00 <b>Rapid development to automated scale: Agile response to support SARS-CoV-2 vaccines and therapeutics</b></p> <p><b>Dr Luc Gagnon</b>, Vice President, Vaccine Sciences, <b>Nexelis</b></p>	<p>15:00 <b>Antimicrobial resistance – title TBC</b></p> <p><b>Shelley McLendon</b>, Vice President, Vaccine and Infectious Disease, <b>ICON &amp; Caroline Forkin</b>, Vice President, Global Research Services, Government and Public Health Solutions, <b>ICON</b></p>	<p>15:00 <b>Combining single cell transcriptomics with antibody repertoire sequencing, in order to map the germinal centre response in fine detail</b></p> <ul style="list-style-type: none"> <li>- Investigating the human immune system with the tonsil as a model to understand normal immune process</li> </ul> <p><b>Dr Louisa James</b>, Lecturer in Immunology, Blizard Institute, <b>Queen Mary University of London</b></p>
			<p>15:15 <b>STriTuVaD simulation platform: A computational platform to predict the effects of vaccines</b></p> <p>Invited: <b>Prof Francesco Pappalardo</b>, Scientific Coordinator, <b>STriTuVaD project</b></p>
Afternoon break	15:30 – 16:00 Expo & Partnering Break		
Afternoon Sessions	<p>16:00 <b>Risk Assessment of SARS-CoV-2 variants of interest and impact on vaccine escape</b></p> <p><b>Dr Bassam Hallis</b>, Head of Pre-Clinical Dev &amp; General Project Manager, National Infection Service, <b>Public Health England</b></p>	<p>16:00 <b>The future of vaccine clinical trials in the post-COVID era</b></p> <p><b>Martina Kovac, M.D.</b>, Vice President, Global Product Development, Vaccines, <b>PPD</b></p>	<p><b>Adjuvants</b></p> <p>16:00 <b>Next generation saponin adjuvant: First-in-human clinical trial results</b></p> <p><b>Dr Tyler Martin</b>, CEO, <b>Adjuvance Technologies</b></p>

16:30 **Comparing COVID-19 vaccine schedule combinations - Com-COV2 study findings so far**  
**Dr Matthew Snape**, Professor in Paediatrics & Vaccinology, **University of Oxford**

16:45 *Reserved*

17:00 – 17:15 **Development of a multiplexed and high-throughput SARS-CoV-2 serology assay**  
**Dr Gemma Moncunill**, Assistant Research Professor, **IS Global**

17:30 *Title TBC*

**Senior representative, Sartorius**

16:30 **Control potential viral contaminants in vaccines and biologics with effective testing**

**Margaret Temple**, Business Development Director, **SGS**

17:00 **Successful execution of a Phase 3 COVID-19 vaccine clinical trial – final title TBC**

**Senior representative, Accelerated Enrollment Solutions (AES)**

17:30 *Reserved*

16:15 **Co-development of a GMP emulsion-based adjuvant for human prophylactic vaccines**

16:30 **Panel: What will the role of adjuvants be in future pandemic preparedness?**

*Panellists to be announced*

18:00 Sponsored Evening Networking Drinks

End of day 1

# Oct 20, 2021

Oct 20 Day 2		KEYNOTES			
Morning plenary sessions	08:00 – 09:00 <b>Keynote: Impact of mRNA vaccines and new generation of vaccines for the world</b> <ul style="list-style-type: none"> <li>- What is the future for mRNA vaccines for future pandemics, existing infectious diseases and cancer?</li> <li>- Will RNA vaccines be accessible and sustainably produced for worldwide use?</li> </ul> <b>Dr Andreas Kuhn</b> , Senior Vice President RNA Biochemistry & Manufacturing, <b>BioNtech</b> <b>David Hering</b> , Global mRNA Business & Franchise Lead, <b>Pfizer</b> <b>Kumaran Vadivelu</b> , Vice President, Vaccine Development Team Leader, <b>GSK Vaccines</b> <b>Invited: Moderna</b>				
	09:00 – 10:00 <b>Keynote: Should we be vaccinating children with the new COVID vaccines &amp; what is our strategy with other population/age groups?</b> <ul style="list-style-type: none"> <li>- What do we know about paediatric &amp; maternal immunisation with these new vaccines?</li> <li>- What risk does SARS-Cov-2 pose to the new-born?</li> <li>- Strategy and vaccine considerations to vulnerable groups</li> </ul> <b>Dr Gregory Glenn</b> , President R&D, <b>Novavax</b> <b>Dr Randall Hyer</b> , Head of Medical Affairs, <b>Moderna</b> <b>Prof Carl S. Goodyear</b> , Director of GLAZgo Discovery Centre, Senior Senate Assessor on Court, Professor of Translational Immunology, Institute of Infection, Immunity and Inflammation, College of Medical, Veterinary and Life Sciences, <b>University of Glasgow</b> <i>More speakers to be announced shortly</i>				
Morning break	10:00 – 10:30 Expo & Partnering Break				
Tracks	One Health	AMR & Bacterial Vaccines <i>Chair: Dr Jan Poolman, Head Bacterial Vaccine Discovery and Early Development, Janssen</i>	Bioprocess & Manufacturing	Respiratory Diseases	
Afternoon Sessions	10:30 – 11:30 <b>Panel: ZAPI as a model for surge vaccine development and production</b> <b>Moderator: Joris Vandeputte</b> , President, IABS <b>Jean-Christophe Audonnet</b> , Senior Director, <b>Boehringer Ingelheim Animal Health</b> & Coordinator of <b>ZAPI IMI Project</b> <b>Dr Elisabeth Erlacher-Vindel</b> , Head of the Antimicrobial Resistance and Veterinary Products Department, <b>OIE</b> <b>Prof Ab Osterhaus</b> , Director, Research Center For Emerging Infections And Zoonoses (Riz),	10:30 <b>WHO strategy, pathogen priorities and role of vaccines</b> <b>Dr Isabel Frost</b> , Consultant, Vaccines and AMR, <b>WHO</b>	10:30 <b>Presentation - title TBC</b> <b>Senior representative, Leukocare</b> 10:45 <b>Large-scale production of subunit vaccines in a bioreactor-free system</b> <b>Dr Jose Escribano</b> , CSO, <b>Algenex</b>	10:30 - 11:30 <b>Panel: Clinical development learnings from COVID-19</b> <ul style="list-style-type: none"> <li>- Correlates of protection</li> <li>- Heterologous priming and boosting strategies</li> <li>- Variant-adapted vaccines</li> <li>- Planning Phase 3 ahead, country selection etc.</li> <li>- Safety signals popping up during vaccine roll out phase, communication strategies</li> <li>- Regulatory lessons learned</li> </ul>	
		11:00 – 12:00 <b>CARB-X supported companies and pipeline updates</b> <i>Moderated by Ed Buurman</i> , Alliance Director, <b>CARB-X</b> <ul style="list-style-type: none"> <li>- <b>GAS</b> <b>Dr Jeff Fairman</b>, Vice President of Research and Founder, <b>VaxCyte</b></li> <li>- <b>N.gonorrhoeae</b></li> </ul>	<b>Expediting Viral-Based Vaccines Development in a Pandemic Situation - TBC</b> <b>Senior representative, Sartorius</b>		



**University of Veterinary  
Medicine Hannover**  
**Stig Tollefsen**, Technology  
Office Lead, **CEPI**

**Dr Calman MacLennan**,  
Professor of Vaccine  
Immunology, **Jenner  
Institute**  
- **Kleb-Acinteo-Pseudo**  
**Dr Juanjo Infante**, CEO,  
**Vaxdyn**

*Moderator:* **Dr Jakob  
Cramer**, Head of Clinical  
Development, **CEPI**

**Dr Matthew Snape**,  
Professor in Paediatrics &  
Vaccinology, **University of  
Oxford**

**Invited speakers:**  
**Dr Peter Dull**, Deputy  
Director, Integrated  
Clinical Vaccine  
Development, **Bill &  
Melinda Gate Foundation**

**Dr Lidia Oostvogels**,  
**CureVac - TBC**

**Dr Robert Chen**, Scientific  
Director, **Brighton  
Collaboration - TBC**

**Dr Marco Cavaleri**, Head  
of Office, Anti-infective  
and Vaccines in the  
Human, Medicines  
Evaluation Division, **EMA -  
TBC**

11:30 **Tackling  
coronaviruses with cross-  
reactive monoclonal  
antibodies**

**Dr Berend Jan Bosch**,  
Faculty of Veterinary  
Medicine, **Utrecht  
University**

11:30 **Biomanufacturing  
technology advances for  
accelerated and  
decentralized vaccine  
manufacturing (COVID19  
case study)**

**Senior representative,  
Univercells**

11:30 **India's COVID  
vaccine pipeline**

11:45 **An enzymatic  
nucleic acid vaccine  
platform optimised for  
global pandemic  
response**

**Dr Jill Makin**, Chief  
Technology Officer,  
**Touchlight**

11:45 **COVAC-2: a S1  
subunit-based COVID-19  
vaccine adjuvanted with  
Sepivac SWE™**

**Trina Racine**, Associate  
Director, Vaccine  
Development, **VIDO**

12:00 **Epidemiology of  
bacteremia and sepsis**

12:00 **Vaccine processing,  
manufacturing strategies**

12:00 **Trial update on  
Novavax's COVID vaccine**

	<p>12:00 <b>Combatting Nipah Virus: Developing a vaccine for pigs</b>  <b>Dr Dalan Bailey</b>, Group Leader, Cell Biology, Innate Immunity, Molecular Virology, Proteomics, Viral Diseases, <b>The Pirbright Institute</b></p>	<p><b>Dr Thomas Verstraeten</b>, CEO, <b>P-95</b>  12:15 <b>E.coli vaccines</b>  <b>Dr Jan Poolman</b>, Head Bacterial Vaccine Discovery and Early Development, <b>Janssen</b></p>	<p><b>to accelerate Innovation &amp; speed</b>  <b>Jérôme Dalin</b>, EMEA Core Modalities Strategy operationalization – Senior Consultant – Bioprocessing, <b>Merck KGaA</b></p>	<p><b>Dr Gregory Glenn</b>, President R&amp;D, <b>Novavax</b></p>
Lunch Break	12:30 – 14:00 Expo & Partnering Break			
Afternoon Sessions	<p>14:00 – 15:00 <b>Panel: Novel approaches to human and animal vaccine development</b>  <b>Moderator: Dr Vish Nene</b>, Co-leader Animal and Human Health program, <b>International Livestock Research Institute</b>  <b>Dr Neil King</b>, Assistant Professor, The Institute for Protein Design, <b>University of Washington</b>  <b>Prof John Hammond</b>, Group Leader, Genetics, Genomics, Immunology, <b>The Pirbright Institute</b>  <b>Fred Fellouse</b>, Senior Research Associate, <b>The Donnelly Centre, University of Toronto</b></p>	<p>14:00 <b>Presentation: TB</b></p> <p>14:15 <b>Presentation: Staph aureus</b></p> <p>14:30 <b>Presentation: c.diff</b>  <b>Dr Annaliesa Anderson</b>, CSO Bacterial Vaccines, <b>Pfizer</b></p>	<p>Presentation title TBC  <b>Senior representative, Kuhner Shaker</b>  <b>Modified vaccinia virus ankara: Platform based development and manufacturing</b>  <b>Dr Simone Kardinahl</b>, Vice President Development, <b>IDT Biologika</b></p> <p><b>Reserved: ultraDAWN: real-time DSP analytics using light scattering</b>  <b>Dr Dan Some</b>, Principal Scientist, <b>Wyatt Technology Corp.</b></p> <p>14:45 <b>COVID case studies: Process development and fixed based reactors - TBC</b>  <b>Senior representative, Batavia Biosciences</b></p>	<p>14:00 <b>COVID vaccine update</b>  <b>Dr Hanneke Schuitemaker</b>, VP, Viral Vaccine Discovery and Translational Medicine, <b>Janssen Vaccines</b></p> <p>14:30 <b>Are we ready and prepared for the upcoming flu season?</b>  <b>Lyn Morgan Marsden</b>, Senior Director Public Affairs, <b>Sanofi &amp; IFPMA Vaccines Committee Chair</b></p>
	<p>15:00 <b>Rift valley fever: Developing the world's first vaccine suitable for humans and livestock</b>  Invited: <b>George Warimwe</b>, Group Leader, <b>KEMRI-Wellcome Trust Research Programme, Kenya</b>; Associate Professor, Centre for Tropical Medicine &amp; Global Health, <b>University of Oxford</b></p>	<p>Panel: <b>How do we assess the value of vaccine preventable AMR diseases?</b></p> <ul style="list-style-type: none"> <li>- Antibiotic awareness</li> <li>- Future strategy to protect the aging population and pneumococcal vaccinations</li> <li>- How do we assess value?</li> <li>- Economic and public health burden of AMR</li> </ul> <p><b>Moderator:</b></p>	<p><b>Bioprocessing challenges of adjuvanted vaccine development</b>  <b>Dr Charles Lutsch</b>, AVP R&amp;D Enabling Sciences &amp; Head Adjuvant Center, <b>Sanofi Pasteur</b></p> <p><b>Increasing vaccine production using Viral Sensitizer Technology</b>  <b>Reserved for Dr Jean-Simon Diallo</b>, CEO &amp; Scientific Founder, <b>Virica Biotech Inc</b></p>	<p>15:00 <b>Universal flu vaccines</b></p>

	<p>15:30 <b>Large animal challenge models for assessment of human and veterinary negative strand virus recombinant vaccines</b></p>	<p><b>Dr Jan Poolman</b>, Head Bacterial Vaccine Discovery and Early Development, <b>Janssen</b>  <b>Dr Mateusz Hasso-Agopsowicz</b>, Technical Officer &amp; Project Manager, Vaccine Product &amp; Delivery Research  Immunization, Vaccines and Biologicals (IVB), <b>WHO</b>  <b>Dr Anthony Fiore</b>, MD, MPH, Chief, Epidemiology Research and Innovations Branch, Division of Healthcare Quality Promotion, NCEZID, <b>CDC</b>  <b>Dr Charlie Weller</b>, Head of Vaccines, <b>Wellcome Trust</b></p>	<p>15:30 – 16:30 <b>Panel: How will we better deliver more sustainable vaccine manufacturing during outbreaks?</b></p> <ul style="list-style-type: none"> <li>- How to establish regional health security</li> <li>- The need to develop a long-term manufacturing road map</li> <li>- Identifying manufacturing capacity and capability</li> </ul> <p><i>Moderator: Paula Barbosa</i>, Associate Director, Vaccine Policy, <b>IFPMA</b>  <b>Dr Matthew Downham</b>, Sustainable Manufacturing Lead, <b>CEPI</b>  <b>Matthew Duchars</b>, CEO, <b>The Vaccines Manufacturing &amp; Innovation Centre</b>  <b>Martin Friede</b>, Coordinator, Initiative for Vaccine Research (IVR), <b>WHO</b>  <b>Vivian Hsu</b>, Deputy Director Strategy Planning and Management, Vaccine Development &amp; Surveillance, <b>BMGF</b></p>	<p>15:30 <b>RSV vaccines</b>  <b>Reserved for Icosavax</b></p> <p>15:45 <b>RSV vaccines</b></p>
Break	16:00 – 16:30 Afternoon Expo & Partnering Break			
<b>KEYNOTE</b>				
Closing Plenary	<p>16:30 – 17:30 <b>Keynote panel – how can we better collaborate with a one health approach to prepare for the next pandemic?</b></p> <ul style="list-style-type: none"> <li>- What are the next pathogens likely to be?</li> <li>- Will they be Respiratory? Arthropod borne? Faeco-oral? Sexually transmitted? Or antibiotic resistant bacteria?</li> <li>- Making pan-universal vaccines for groups of viruses</li> <li>- Is a 100 day moon-shot timeline achievable for future emerging diseases outbreaks?</li> </ul> <p><b>Dr Josep Jansa</b>, Acting Head of Section Support/Group Leader, Response and Emergency Operations, <b>European Centre for Disease Prevention and Control (ECDC)</b>  <b>Dr Dalan Bailey</b>, Group Leader, Cell Biology, Innate Immunity, Molecular Virology, Proteomics, Viral Diseases, <b>The Pirbright Institute</b>  <b>Senior representative, WHO</b>  <b>Senior representative, CEPI</b></p>			
18:00 Sponsored Evening Networking Drinks End of day 2				

# Oct 21, 2021

## DEDICATED TRACK SESSIONS

Oct 21 Day 3		DEDICATED TRACK SESSIONS		
9:00 – 9:30		Morning Networking		
Tracks	Emerging Disease X	Immuno-Oncology Profiling	Logistics, Delivery & Access	
Morning Sessions	<p>09:30 – 10:30 <b>What's on our priority pathogens list?</b></p> <ul style="list-style-type: none"> <li>- Progress on Chik, Nipah, Lassa, Ebola</li> <li>- Investing in research early for non commercial vaccines</li> <li>- Building a sustainable preparedness model</li> </ul> <p><b>Senior representative, WHO</b></p> <p><i>More panellists TBC</i></p>	<p>09:30 <b>SARS-CoV-2 vaccines and cancer patients</b></p> <p><b>Dr Giuseppe Curigliano</b>, Director, New Drugs and Early Drug Development for Innovative Therapies, <b>European Institute of Oncology</b></p>	<p>09:30 <b>Decentralized trials: How to develop a flexible supply chain strategy</b> – Title TBC</p> <p><b>Senior representative, Marken</b></p>	
		<p>10:00 <b>How to match tumour mutanomes to improve immune responses</b></p> <p><b>Prof Wim Van Criekinge</b>, CSO, myNEO</p>	<p>10:00 <b>Presentation</b> – Title TBC</p> <p><b>David Hipkiss</b>, CEO, <b>Enesi Pharma</b></p>	
		<p>10:30 <b>Panel: Early-stage immuno-oncology clinical trials and the importance of understanding mechanisms in human subjects</b></p> <ul style="list-style-type: none"> <li>- Discussing deficiencies in preclinical models</li> <li>- Exploring how newer technologies are powering translational medicine</li> <li>- Designing early-stage studies to maximise the chances of success</li> </ul> <p><b>Moderator: Dr Philip Beer</b>, Physician Scientist And Precision Oncology Specialist, <b>Sanger Institute</b></p> <p><b>Dr Giuseppe Curigliano</b>, Director, New Drugs and Early Drug Development for Innovative Therapies, <b>European Institute of Oncology</b></p> <p><b>Katja Rybakova</b>, Founder, <b>Cellgebra</b> &amp; Senior Researcher, <b>Royal College of Surgeons Ireland</b></p> <p><i>More panellists to be announced</i></p>	<p>10:15 <b>Progress of COVID-19 vaccines with needle-free delivery</b></p> <p><b>Erin Spiegel</b>, VP of Clinical and Regulatory Affairs, <b>Pharmajet</b></p>	
		<p>10:30 <b>Vaxchora® (Cholera Vaccine, live, oral) in Children and Adolescents – A Review</b></p> <p><b>Dr Mark Schneider</b>, Sr. Director, Global Medical Affairs - Vaccines and Therapeutics, <b>Emergent Biosolutions</b></p> <p>11:00 <b>Progress with malaria vaccination</b></p> <p><b>Dr Adrian Hill</b>, Professor, <b>University of Oxford</b></p>		<p>10:30 <b>Presentation:</b></p> <p><b>Senior representative, Viroclinics</b></p>
			<p>11:00 <b>A pre-IND versatile nanocomplex formed by electrokinetic force for mRNA vaccine delivery / adjuvant</b></p> <ul style="list-style-type: none"> <li>- Delivery with good ordinary cold chain stability and balanced Th1 / Th2 immunogenicity</li> <li>- Formed with bio-degradable materials with clean GLP profile</li> </ul> <p><b>Jason Huang</b>, CMO, <b>Ascendo Biotech</b></p>	
			<p>11:15 <b>Oromucosal vaccine delivery platform</b></p> <p><b>Patrik Komárek</b>, Chairman, <b>InStar Technologies</b></p>	

Break		11:30 – 12:30 Expo & Partnering Brunch Break	
Afternoon Sessions	<p><b>12:30 – 13:30 Panel: Is it feasible to develop universal/pan corona vaccines?</b>  <i>Moderator: Dr Maria Elena Bottazzi, Associate Dean, National School of Tropical Medicine &amp; Co-Section Head, Pediatric Tropical Medicine</i></p> <p><b>Prof Ab Osterhaus, Director, Research Center For Emerging Infections And Zoonoses (Riz), University of Veterinary Medicine Hannover</b></p> <p><b>Ronald Kempers, Mymetics – invited</b></p> <p><i>More panellists to be announced</i></p>	<p style="background-color: #c00000; color: white; text-align: center;"><b>Therapeutic Vaccines</b></p> <p><b>12:30 Update on Vaccitech’s therapeutic hepatitis B program</b>  <b>Dr Thomas Evans, CSO &amp; Board Director, Vaccitech</b></p> <p><b>12:50 Progress in combination immunotherapy of cancer involving therapeutic vaccination</b>  <b>Cornelis Melief, Chief Scientific Officer, ISA Pharmaceuticals</b></p> <p><b>13:10 Developing personalized neoantigen cancer vaccines to target solid tumors</b>  <b>Agnete B. Fredriksen, Chief Innovation &amp; Strategy Officer, Vaccibody AS</b></p>	<p><b>12:30 – 13:30 Panel: Strengthening immunization programs and recovering routine immunization rates</b></p> <ul style="list-style-type: none"> <li>- Vaccine alliances, policy and access</li> <li>- Risks of measles and other vaccine-preventable disease outbreaks re-emerging as a result of un/under-vaccination during the pandemic</li> <li>- Addressing various factors, such as public discomfort in accessing the healthcare system for fear of contracting COVID, disruptions to immunization programs, diversion of staff/resources, etc.</li> </ul> <p><b>Dr Julia Spencer, Associate Vice President, Global Public Policy, MSD</b></p> <p><b>Jean-Cédric Meeùs, Chief Transport, UNICEF Supply Division</b></p> <p><b>Ingrid Keller, European Commission, Acting Head Chronic Disease and Health Programme Unit, DG Health and Food Safety</b>  <i>More panellists to be announced</i></p>
	<b>13:30 Presentation</b>	<b>13:30 – 14:30 How do we build a better, more successful immuno-oncology clinical development paradigm?</b>	<b>13:30 – 14:30 Panel: Insights on how to implement new partnership models for international collaboration among vaccine manufacturers, NGOs and government</b>
	<b>14:00 Presentation</b>	<ul style="list-style-type: none"> <li>- Obstacles in current IO drug &amp; therapeutic development</li> <li>- Discussing how the immuno-oncology field has hit an asymptote in therapeutic gains using the current models of cancer drug development</li> <li>- How can we improve the immuno-oncology drug development pipeline by using earlier stage nimble trials?</li> </ul> <p><i>Moderator: Dr Laszlo Radvanyi, President and Scientific Director, Ontario Institute for Cancer Research</i></p>	<ul style="list-style-type: none"> <li>- How do we continue to pursue International collaborative research and partnering opportunities for vaccine development?</li> <li>- What gaps and other challenges do we still face in order to deliver enough COVID vaccines globally?</li> </ul> <p><b>Professor Jeffrey W. Almond PhD, FMedSci. Visiting Professor of Microbiology, University of Oxford</b></p>

		<p><b>Cornelis Melief</b>, Chief Scientific Officer, <b>ISA Pharmaceuticals</b>  <i>More panellists to be announced</i></p>	<p><b>Dr Satish Ravetkar</b>, Executive Director, <b>Serum Institute of India</b>  <b>Jean-Cédric Meeùs</b>, Chief Transport, <b>UNICEF Supply Division</b>  <b>Dr Maria Elena Bottazzi</b>, Associate Dean, <b>National School of Tropical Medicine</b> &amp; Co-Section Head, <b>Pediatric Tropical Medicine</b>  <b>Neil Jones</b>, Chief Business Officer, <b>The Vaccines Manufacturing &amp; Innovation Centre</b>  <i>More panellists to be announced</i></p>
Break	14:30 – 15:00 Expo & Partnering Afternoon Break		
<b>KEYNOTE</b>			
Closing Plenary	<p>15:00 – 16:00 <b>Vaccine confidence: What has the uptake of our COVID vaccines been globally?</b></p> <ul style="list-style-type: none"> <li>- When will the majority of the population be vaccinated and protected from COVID?</li> <li>- What hurdles do we face that could prevent us from achieving our goals?</li> <li>- Why are there such differences between countries? Has vaccine distribution been fair?</li> <li>- Tackling misinformation</li> <li>- The impact of the pandemic on routine immunization programs</li> </ul> <p><b>Dr Heidi Larson</b>, Professor of Anthropology, Risk and Decision Science, <b>LSHTM</b>  <b>Dr John Markels</b>, President of Global Vaccines, <b>MSD</b>  <b>Dr Thomas Breuer</b>, CMO, <b>GSK Vaccines</b>  <b>Lisa Menning</b>, Technical Officer (Department of Immunization, Vaccines, and Biologicals), <b>WHO</b>  <b>Isabel de la Mata</b>, Principal Advisor for Health and Crisis management, <b>European Commission, DG Health and Food Safety</b></p>		
	16:00 End of congress		



---

## EVENT TEAM

### SPEAKING OPPORTUNITIES

**Wing-Yun Cheung**

wing-yun.cheung@terrapinn.com

**Nadia Konneh**

nadia.konneh@terrapinn.com

### SPONSORSHIP & EXHIBITION

**Marc Rhys- Evans**

marc.rhys-evans@terrapinn.com

**Oliver Breed**

oliver.breed@terrapinn.com

### MARKETING OPPORTUNITIES

**Karina Kusova**

Karina.kusova@terrapinn.com

---

